PT  - JOURNAL ARTICLE
AU  - Edridge, Arthur W. D.
AU  - Kaczorowska, Joanna
AU  - Hoste, Alexis C. R.
AU  - Bakker, Margreet
AU  - Klein, Michelle
AU  - Jebbink, Maarten F.
AU  - Matser, Amy
AU  - Kinsella, Cormac M.
AU  - Rueda, Paloma
AU  - Prins, Maria
AU  - Sastre, Patricia
AU  - Deijs, Martin
AU  - van der Hoek, Lia
TI  - Human coronavirus reinfection dynamics: lessons for SARS-CoV-2
AID  - 10.1101/2020.05.11.20086439
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.11.20086439
4099  - http://medrxiv.org/content/early/2020/05/18/2020.05.11.20086439.short
4100  - http://medrxiv.org/content/early/2020/05/18/2020.05.11.20086439.full
AB  - In the current SARS-CoV-2 pandemic a key unsolved question is the quality and duration of acquired immunity in recovered individuals. This is crucial to solve, however SARS-CoV-2 has circulated for under five months, precluding a direct study. We therefore monitored 10 subjects over a time span of 35 years (1985-2020), providing a total of 2473 follow up person-months, and determined a) their antibody levels following infection by any of the four seasonal human coronaviruses, and b) the time period after which reinfections by the same virus can occur. An alarmingly short duration of protective immunity to coronaviruses was found by both analyses. We saw frequent reinfections at 12 months post-infection and substantial reduction in antibody levels as soon as 6 months post-infection.ONE SENTENCE SUMMARY Coronavirus protective immunity is short-lastingCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a grant from the European Union's Horizon 2020 research and innovation programme, under the Marie Sklodowska-Curie Actions grant agreement no. 721367 (HONOURs), Amsterdam UMC funding connected to HONOURs, and the Amsterdam UMC PhD scholarship of A.W.D. Edridge.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available upon request from the authors